Self-copying RNA vaccine wins first full approval: what’s next?
Elie Dolgin • December 6, 2023
Researchers look ahead to the potential uses and benefits of a technology that has been more than 20 years in the making.
The approval of yet another RNA-based vaccine for COVID-19 might not seem momentous. But the endorsement last week by Japanese authorities of a jab against SARS-CoV-2 constructed using a form of RNA that can make copies of itself inside cells — the first ‘self-amplifying’ RNA (saRNA) granted full regulatory approval anywhere in the world — marks a pivotal advance.
The new vaccine platform could provide potent defence against various infectious diseases and cancers. And because it could be used at a lower dose, it might have fewer side effects than other messenger RNA (mRNA) treatments have.
Continue reading at Nature.
‘Directed’ evolution in the laboratory creates an editing tool that outperforms classic CRISPR systems.
With organoids, assembloids and a growing bioengineering toolkit, scientists are pushing the limits of human brain models.